- Shares of Ocera Therapeutics (OCRX +7.7%) have maintained their momentum and are up sharply in afternoon trading.
- Details from Stifel's coverage initiation are available.
- "We believe the combination of palatable clinical development risk, steady data/news flow, strong patent estate, and potential to meaningfully improve the treatment algorithm in an already greater than $1B HE market opportunity with a rapidly expanding patient demographic creates a highly favorable risk/reward at these levels," analyst Stephen Willey says.
Stifel sees "highly favorable" risk/reward profile for Ocera Therapeutics
Dec 30 2013, 14:50 ET